I-Mab (NASDAQ:NBP - Get Free Report) insider Mark Arnold Hagler bought 230,000 shares of the stock in a transaction dated Friday, April 24th. The shares were acquired at an average price of $2.51 per share, for a total transaction of $577,300.00. Following the completion of the purchase, the insider directly owned 230,000 shares in the company, valued at approximately $577,300. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.
I-Mab Stock Performance
NASDAQ NBP opened at $2.39 on Wednesday. The firm's 50-day simple moving average is $2.80. I-Mab has a 52 week low of $0.81 and a 52 week high of $6.79. The stock has a market capitalization of $276.40 million, a P/E ratio of -6.64 and a beta of 1.74.
I-Mab (NASDAQ:NBP - Get Free Report) last posted its quarterly earnings data on Wednesday, April 8th. The company reported ($0.30) earnings per share for the quarter. As a group, equities research analysts expect that I-Mab will post -0.81 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities analysts have recently weighed in on NBP shares. HC Wainwright restated a "buy" rating and set a $9.00 price target on shares of I-Mab in a report on Wednesday, April 8th. Wall Street Zen cut I-Mab from a "hold" rating to a "sell" rating in a report on Saturday, April 11th. Finally, Weiss Ratings assumed coverage on I-Mab in a report on Thursday, February 5th. They set a "sell (d-)" rating on the stock. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $9.00.
Check Out Our Latest Stock Analysis on I-Mab
Hedge Funds Weigh In On I-Mab
An institutional investor recently bought a new position in I-Mab stock. Brooklyn Investment Group acquired a new position in shares of I-Mab (NASDAQ:NBP - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 12,715 shares of the company's stock, valued at approximately $51,000. Hedge funds and other institutional investors own 38.38% of the company's stock.
I-Mab Company Profile
(
Get Free Report)
I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.
Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
